Abstract Details

Title The Utilization of EEG Monitoring in Premature Infants with High-Grade Intraventricular Hemorrhage

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-004

Objective

We aimed to study the utility of continuous video electroencephalographic (cvEEG) monitoring as a screening tool for seizures in asymptomatic neonates found to have high-grade IVH.

Background High-grade intraventricular hemorrhage (IVH) is one of the possible complications of prematurity, and is considered one of the leading causes of seizures in premature infants. Neonatal seizures can be challenging to detect based on clinical symptoms alone and if left untreated, it can be associated with short- and long-term consequences.

Design/Methods We performed a comprehensive retrospective review on all premature infants born at the University of Alabama at Birmingham Regional Neonatal Intensive Care Unit from June 2018 to June 2021. We selected asymptomatic infants found to have high-grade (grade 3 and 4) IVH on head ultrasound who underwent cvEEG monitoring. Patient characteristics and comorbidities were then carefully studied and correlated with the screening EEG findings.

Results

Among 27 premature infants with IVH enrolled in this study, 7 infants (26%) were found to have seizures detected on EEG. Detected seizures were only subclinical in 5 infants, while 2 infants had clinical in addition to subclinical seizures. Infants with seizures were relatively more premature, had a higher degree IVH, and lower APGAR scores at birth when compared to infants with no seizures.

Conclusions

Our study suggests that EEG monitoring is vital when resources permit to screen for subclinical seizures in infants born with high-grade IVH. EEG screening should start as soon as IVH is suspected or discovered on imaging as early detection of seizures aid in prompt treatment. Since EEG monitoring is resource intensive, we suggest studying additional variables such as the degree of prematurity and APGAR scores to increase the yield of such screening studies.

Authors/Disclosures
Khaled Al Robaidi, MD PRESENTER	Dr. Al Robaidi has nothing to disclose.
Monisha Goyal, MD	Dr. Goyal has nothing to disclose.
Kathryn B. Lalor, MD (University of Alabama at Birmingham)	The institution of Dr. Lalor has received research support from UCB. Dr. Lalor has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker with AAN. Dr. Lalor has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker with AAPC. Dr. Lalor has received personal compensation in the range of $0-$499 for serving as a DSMB Chair with UAB/NIH Grant.
	No disclosure on file
Salman Rashid, MD (Department of Pediatrics Division of Neurology)	Dr. Rashid has nothing to disclose.

��ɫ��

��ɫ��